CELZ's Quick Ratio is ranked better than 92% of 1412
companies
in the Biotechnology industry
Industry Median: 3.6
vs CELZ: 19.67
Creative Medical Technology Holdings (NAS:CELZ) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Creative Medical Technology Holdings Quick Ratio Related Terms
Creative Medical Technology Holdings Quick Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Creative Medical Technology Holdings Quick Ratio Chart
For the Biotechnology subindustry, Creative Medical Technology Holdings's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Creative Medical Technology Holdings Quick Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Creative Medical Technology Holdings's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Creative Medical Technology Holdings's Quick Ratio falls into.
Creative Medical Technology Holdings Quick Ratio Calculation
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Creative Medical Technology Holdings (CELZ) has a Quick Ratio of 19.67 as of Mar. 2026. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Creative Medical Technology Holdings and its competitors. This is 3914% above median its historical median of 0.49. Over the past decade, Creative Medical Technology Holdings' Quick Ratio has ranged from 0.01 to 58.79. According to the industry distribution chart, Creative Medical Technology Holdings ranks #113 out of 1412 companies in the Biotechnology industry, placing it in the top 8%.
Is Creative Medical Technology Holdings' Quick Ratio too high?
Creative Medical Technology Holdings' current Quick Ratio of 19.67 is 3914% above median its 10-year median of 0.49. Over the past 10 years, this metric has ranged from a low of 0.01 to a high of 58.79. The Biotechnology industry median Quick Ratio is 3.60. Creative Medical Technology Holdings' value of 19.67 is 446.4% above this industry median. Based on the distribution chart, Creative Medical Technology Holdings ranks #113 out of 1412 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Creative Medical Technology Holdings has a GF Score™ of 34/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Creative Medical Technology Holdings' Quick Ratio compare to FBLG and GLMD?
According to the Biotechnology industry distribution chart, Creative Medical Technology Holdings ranks #113 out of 1412 companies for Quick Ratio. This places Creative Medical Technology Holdings in the top 8% of its industry — outperforming the majority of peers. The industry median Quick Ratio is 3.60. Creative Medical Technology Holdings' value of 19.67 is 446.4% above this benchmark. Historically, Creative Medical Technology Holdings' own Quick Ratio has ranged from 0.01 to 58.79 over the past decade. While the company's 10-year median is 0.49 vs. the industry median of 3.60, Creative Medical Technology Holdings has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Biotechnology company?
The median Quick Ratio among Biotechnology companies is 3.60, based on 1,412 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Creative Medical Technology Holdings's current Quick Ratio of 19.67 is 446.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Creative Medical Technology Holdings and its competitors. For the Biotechnology industry, the median Quick Ratio is 3.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Creative Medical Technology Holdings's current Quick Ratio is 19.67, which is 3914% above median its own 10-year median of 0.49. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Creative Medical Technology Holdings stock overvalued right now?
Based on GuruFocus' analysis, Creative Medical Technology Holdings (CELZ) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.32, compared to a current price of $0.81 — trading 153.2% above its estimated fair value. The current Quick Ratio is 19.67, which is 3914% above median its 10-year median of 0.49 and 446.4% above the Biotechnology industry median of 3.60. Creative Medical Technology Holdings' overall GF Score™ is 34/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Creative Medical Technology Holdings (CELZ), the current Quick Ratio is 19.67 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Creative Medical Technology Holdings (CELZ) Overvalued in 2026?
Based on GuruFocus' analysis, Creative Medical Technology Holdings stock appears to be overvalued.
The current stock price of $0.81 is trading 153.2% above its estimated GF Value™ of $0.32.
GuruFocus considers Creative Medical Technology Holdings to be Significantly Overvalued.
Key valuation signals for CELZ:
Quick Ratio: 19.67 (3914% above median its 10-year median of 0.49)
GF Value™: $0.32 vs. price of $0.81 (153.2% above fair value)
Industry Position: 446.4% above the Biotechnology median (#113 of 1412)
No single metric tells the full story. See the CELZ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Creative Medical Technology Holdings Business Description
Creative Medical Technology Holdings Inc is a commercial-stage biotechnology company focused on the advancement of regenerative therapies in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics. Its pipeline consists of AlloStem (CELZ-201-DDT); ImmCelz (CELZ-100), a personalized supercharged immune therapy platform; CELZ-201 CREATE-1, an intervention for the treatment of recent onset Type 1 Diabetes; AlloStemSpine for treatment of lower back pain; the Alova program to treat infertility as a result of premature ovarian failure; and other regenerative treatment programs and technologies like OvaStem, CaverStem, FemCelz, StemSpine, and others for the treatment of various indications related to sexual health, spine disc disease, kidney failure, liver failure, etc.
34GF Score
Get the complete analysis for CELZ
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CELZ has been successfully added to your 
